PT - JOURNAL ARTICLE AU - Robert Fahed AU - Malek Ben Maacha AU - Célina Ducroux AU - Naim Khoury AU - Raphaël Blanc AU - Michel Piotin AU - Bertrand Lapergue ED - , TI - Agreement between core laboratory and study investigators for imaging scores in a thrombectomy trial AID - 10.1136/neurintsurg-2018-013867 DP - 2018 May 14 TA - Journal of NeuroInterventional Surgery PG - neurintsurg-2018-013867 4099 - http://jnis.bmj.com/content/early/2018/05/14/neurintsurg-2018-013867.short 4100 - http://jnis.bmj.com/content/early/2018/05/14/neurintsurg-2018-013867.full AB - Purpose We aimed to assess the agreement between study investigators and the core laboratory (core lab) of a thrombectomy trial for imaging scores.Methods The Alberta Stroke Program Early CT Score (ASPECTS), the European Collaborative Acute Stroke Study (ECASS) hemorrhagic transformation (HT) classification, and the Thrombolysis In Cerebral Infarction (TICI) scores as recorded by study investigators were compared with the core lab scores in order to assess interrater agreement, using Cohen’s unweighted and weighted kappa statistics.Results There were frequent discrepancies between study sites and core lab for all the scores. Agreement for ASPECTS and ECASS HT classification was less than substantial, with disagreement occurring in more than one-third of cases. Agreement was higher on MRI-based scores than on CT, and was improved after dichotomization on both CT and MRI. Agreement for TICI scores was moderate (with disagreement occurring in more than 25% of patients), and went above the substantial level (less than 10% disagreement) after dichotomization (TICI 0/1/2a vs 2b/3).Conclusion Discrepancies between scores assessed by the imaging core lab and those reported by study sites occurred in a significant proportion of patients. Disagreement in the assessment of ASPECTS and day 1 HT scores was more frequent on CT than on MRI. The agreement for the dichotomized TICI score (the trial’s primary outcome) was substantial, with less than 10% of disagreement between study sites and core lab.Trial registration number NCT02523261, Post-results.